Melatonin Attenuates Neuroinflammation by Down-Regulating NLRP3 Inflammasome via a SIRT1-Dependent Pathway in MPTP-Induced Models of Parkinson’s Disease

References

• Li G, Ma J, Cui S, et al. Parkinson’s disease in China: a forty-year growing track of bedside work. Transl Neurodegener. 2019;8:22. doi:10.1186/s40035-019-0162-z
   PubMed Web of Science ®Google Scholar
• Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. doi:10.1038/nrdp.2017.13
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382–397. doi:10.1016/S1474-4422(09)70062-6
   PubMed Web of Science ®Google Scholar
• Haque ME, Akther M, Jakaria M, Kim IS, Azam S, Choi DK. Targeting the microglial NLRP3 inflammasome and its role in Parkinson’s disease. Mov Disord. 2020;35:20–33. doi:10.1002/mds.27874
   PubMed Web of Science ®Google Scholar
• Baroja-Mazo A, Martin-Sanchez F, Gomez AI, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014;15:738–748. doi:10.1038/ni.2919
   PubMed Web of Science ®Google Scholar
• Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21:677–687. doi:10.1038/nm.3893
   PubMed Web of Science ®Google Scholar
• Rathinam VA, Fitzgerald KA. Inflammasome Complexes: emerging Mechanisms and Effector Functions. Cell. 2016;165:792–800. doi:10.1016/j.cell.2016.03.046
   PubMed Web of Science ®Google Scholar
• Lu A, Magupalli VG, Ruan J, et al. Unified Polymerization Mechanism for the Assembly of ASC-Dependent Inflammasomes. Cell. 2014;156:1193–1206. doi:10.1016/j.cell.2014.02.008
   PubMed Web of Science ®Google Scholar
• de Araujo FM, Cuenca-Bermejo L, Fernandez-Villalba E, Costa SL, Silva VDA, Herrero MT. Role of Microgliosis and NLRP3 Inflammasome in Parkinson’s Disease Pathogenesis and Therapy. Cell Mol Neurobiol. 2021. doi:10.1007/s10571-020-01027-6
   PubMed Web of Science ®Google Scholar
• Gordon R, Albornoz EA, Christie DC. et al. Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med;2018. 10. doi: 10.1126/scitranslmed.aah4066
   Web of Science ®Google Scholar
• Lee E, Hwang I, Park S, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2018.
   Web of Science ®Google Scholar
• Tamtaji OR, Reiter RJ, Alipoor R, Dadgostar E, Kouchaki E, Asemi Z. Melatonin and Parkinson Disease: current Status and Future Perspectives for Molecular Mechanisms. Cell Mol Neurobiol. 2020;40:15–23. doi:10.1007/s10571-019-00720-5
   PubMed Web of Science ®Google Scholar
• Alghamdi BS. The neuroprotective role of melatonin in neurological disorders. J Neurosci Res. 2018;96:1136–1149. doi:10.1002/jnr.24220
   PubMed Web of Science ®Google Scholar
• Hardeland R. Melatonin and inflammation-Story of a double-edged blade. J Pineal Res. 2018;65:e12525.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Najafi M, Kavyiani N, Mohammadinejad R, Farkhondeh T, Samarghandian S. Anti-Inflammatory Activity of Melatonin: a Focus on the Role of NLRP3 Inflammasome. Inflammation. 2021. doi:10.1007/s10753-021-01428-9
   PubMed Web of Science ®Google Scholar
• Xu G, Shi D, Zhi Z, Ao R, Yu B. Melatonin ameliorates spinal cord injury by suppressing the activation of inflammasomes in rats. J Cell Biochem. 2019;120:5183–5192. doi:10.1002/jcb.27794
   PubMed Web of Science ®Google Scholar
• Dong Y, Fan C, Hu W, et al. Melatonin attenuated early brain injury induced by subarachnoid hemorrhage via regulating NLRP3 inflammasome and apoptosis signaling. J Pineal Res. 2016;60:253–262. doi:10.1111/jpi.12300
   PubMed Web of Science ®Google Scholar
• Arioz BI, Tastan B, Tarakcioglu E, et al. Melatonin Attenuates LPS-Induced Acute Depressive-Like Behaviors and Microglial NLRP3 Inflammasome Activation Through the SIRT1/Nrf2 Pathway. Front Immunol. 2019;10:1511. doi:10.3389/fimmu.2019.01511
   PubMed Web of Science ®Google Scholar
• Mayo JC, Sainz RM, Gonzalez Menendez P, Cepas V, Tan DX, Reiter RJ. Melatonin and sirtuins: a “not-so unexpected” relationship. J Pineal Res. 2017;62.
   Web of Science ®Google Scholar
• Li X, Feng Y, Wang XX, Truong D, Wu YC. The Critical Role of SIRT1 in Parkinson’s Disease: mechanism and Therapeutic Considerations. Aging Dis. 2020;11:1608–1622. doi:10.14336/AD.2020.0216
   PubMed Web of Science ®Google Scholar
• Pallas M, Pizarro JG, Gutierrez-Cuesta J, et al. Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience. 2008;154:1388–1397. doi:10.1016/j.neuroscience.2008.04.065
   PubMed Web of Science ®Google Scholar
• Singh P, Hanson PS, Morris CM. SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson’s disease. BMC Neurosci. 2017;18:46. doi:10.1186/s12868-017-0364-1
   PubMed Web of Science ®Google Scholar
• Han Y, Sun W, Ren D, et al. SIRT1 agonism modulates cardiac NLRP3 inflammasome through pyruvate dehydrogenase during ischemia and reperfusion. Redox Biol. 2020;34:101538. doi:10.1016/j.redox.2020.101538
   PubMed Web of Science ®Google Scholar
• Park S, Shin J, Bae J, et al. SIRT1 Alleviates LPS-Induced IL-1beta Production by Suppressing NLRP3 Inflammasome Activation and ROS Production in Trophoblasts. Cells. 2020;9.
   PubMed Web of Science ®Google Scholar
• Tu Y, Song E, Wang Z, et al. Melatonin attenuates oxidative stress and inflammation of Muller cells in diabetic retinopathy via activating the Sirt1 pathway. Biomed Pharmacother. 2021;137:111274. doi:10.1016/j.biopha.2021.111274
   PubMed Web of Science ®Google Scholar
• Jimenez-Ferrer I, Backstrom F, Duenas-Rey A, et al. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson’s disease. Brain Behav Immun. 2021;91:369–382. doi:10.1016/j.bbi.2020.10.017
   PubMed Web of Science ®Google Scholar
• Lian H, Roy E, Zheng H. Protocol for Primary Microglial Culture Preparation. Bio Protoc. 2016;6.
   Google Scholar
• Spijker S. Dissection of Rodent Brain Regions. Neuroproteomics. 2011;13–26.
   Google Scholar
• Soderbom G, Zeng BY. The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases. Int Rev Neurobiol. 2020;154:345–391.
   PubMed Web of Science ®Google Scholar
• Chatterjee K, Roy A, Banerjee R, et al. Inflammasome and alpha-synuclein in Parkinson’s disease: a cross-sectional study. J Neuroimmunol. 2020;338:577089. doi:10.1016/j.jneuroim.2019.577089
   PubMedGoogle Scholar
• Chen X, Hu Y, Cao Z, Liu Q, Cheng Y. Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer’s Disease, Parkinson’s Disease and Amyotrophic Lateral Sclerosis: a Systematic Review and Meta-Analysis. Front Immunol. 2018;9:2122. doi:10.3389/fimmu.2018.02122
   PubMed Web of Science ®Google Scholar
• Hanamsagar R, Torres V, Kielian T. Inflammasome activation and IL-1beta/IL-18 processing are influenced by distinct pathways in microglia. J Neurochem. 2011;119:736–748. doi:10.1111/j.1471-4159.2011.07481.x
   PubMed Web of Science ®Google Scholar
• Fan Z, Pan YT, Zhang ZY, et al. Systemic activation of NLRP3 inflammasome and plasma alpha-synuclein levels are correlated with motor severity and progression in Parkinson’s disease. J Neuroinflammation. 2020;17:11. doi:10.1186/s12974-019-1670-6
   PubMed Web of Science ®Google Scholar
• Ye J, Liu Z, Wei J, et al. Protective effect of SIRT1 on toxicity of microglial-derived factors induced by LPS to PC12 cells via the p53-caspase-3-dependent apoptotic pathway. Neurosci Lett. 2013;553:72–77. doi:10.1016/j.neulet.2013.08.020
   PubMed Web of Science ®Google Scholar